VC
ZBIO

VarCov Co’s Zenas BioPharma ZBIO Stock Holding History

VarCov Co’s Portfolio ZBIO Stock Details ZBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$267K Buy
+10,505
New +$209K 0.1% 298
2026
Q1 		– Sell
-7,335
Closed -$266K – 680
2025
Q4 		$266K Buy
+7,335
New +$241K 0.11% 318

Other funds holding ZBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VarCov Co's ZBIO Position: Q2 2026 in Review

VarCov Co opened a new position in Zenas BioPharma (ZBIO) in Q2 2026: 10,505 shares worth $267K. The stake represents 0.1% of the portfolio and ranks #298 among its holdings. This is a return to the name: VarCov Co previously reported a position in ZBIO as recently as Q4 2025.

VarCov Co first reported a position in ZBIO in Q4 2025 and has held it in 2 quarters since. 143 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

  • VarCov Co held 10,505 shares of Zenas BioPharma worth $267K as of Q2 2026.
  • Zenas BioPharma was a new VarCov Co position in Q2 2026.
  • Zenas BioPharma made up 0.1% of VarCov Co's portfolio in Q2 2026, its #298 holding.
  • VarCov Co first reported a position in Zenas BioPharma in Q4 2025 and has held it in 2 quarters since.
  • 143 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on VarCov Co's 13F filing for Q2 2026, filed 14 Aug 2026.